Talazoparib-¹³C,d₄ (Synonyms: BMN-673-¹³C,d₄; LT-673-¹³C,d₄)

Cat. No.: HY-16106S Purity: 99.30%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Talazoparib-¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

For research use only. We do not sell to patients.

Talazoparib-<sup>13</sup>C,d<sub>4</sub> Chemical Structure

Talazoparib-¹³C,d₄ Chemical Structure

Size	Price	Stock	Quantity
100 μg	USD 1500	In-stock	Estimated Time of Arrival: December 31

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Talazoparib-¹³C,d₄:

Talazoparib In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

385.37

Formula

C₁₈¹³CH₁₀D₄F₂N₆O

Unlabeled CAS

1207456-01-6

Appearance

Solid

Color

White to off-white

SMILES

O=C1NN=C2C3=C1C=C(C=C3N[13C@@H]([C@H]2C4=NC=NN4C)C5=C(C([2H])=C(C([2H])=C5[2H])F)[2H])F

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (64.87 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5949 mL	12.9745 mL	25.9491 mL
5 mM	0.5190 mL	2.5949 mL	5.1898 mL
10 mM	0.2595 mL	1.2975 mL	2.5949 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.30%

Select Batch:

Data Sheet (279 KB) SDS (252 KB)

COA (258 KB)

Handling Instructions (2659 KB)

References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]

[2]. Wang B, et al. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. J Med Chem. 2016 Jan 14;59(1):335-57. [Content Brief]

[3]. Shen Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.Clin Cancer Res. 2013 Sep 15;19(18):5003-15. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5949 mL	12.9745 mL	25.9491 mL	64.8727 mL
	5 mM	0.5190 mL	2.5949 mL	5.1898 mL	12.9745 mL
	10 mM	0.2595 mL	1.2975 mL	2.5949 mL	6.4873 mL
	15 mM	0.1730 mL	0.8650 mL	1.7299 mL	4.3248 mL
	20 mM	0.1297 mL	0.6487 mL	1.2975 mL	3.2436 mL
	25 mM	0.1038 mL	0.5190 mL	1.0380 mL	2.5949 mL
	30 mM	0.0865 mL	0.4325 mL	0.8650 mL	2.1624 mL
	40 mM	0.0649 mL	0.3244 mL	0.6487 mL	1.6218 mL
	50 mM	0.0519 mL	0.2595 mL	0.5190 mL	1.2975 mL
	60 mM	0.0432 mL	0.2162 mL	0.4325 mL	1.0812 mL

Talazoparib-¹³C,d₄ Related Classifications

Others

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Talazoparib-¹³C,d₄BMN-673-¹³C,d₄ LT-673-¹³C,d₄Isotope-Labeled CompoundsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Talazoparib-13C,d4 (Synonyms: BMN-673-13C,d4; LT-673-13C,d4)

Other Forms of Talazoparib-13C,d4:

Talazoparib-13C,d4 Related Antibodies